Table 1 Details of patients and controls.
Healthy Controls | Behçet’s Syndrome | |||
|---|---|---|---|---|
General Demographics | ||||
Cohort size | 74 | 88 | ||
Median age (range) | 41 | (18–75) | 43 | (17–74) |
Male sex (%) | 40 | 54% | 47 | 53% |
Current smoker | 6 | 8% | 12 | 14% |
Clinical Characteristics | ||||
Mucocutaneous | — | 88 | 100% | |
Erythema nodosum | — | 29 | 33% | |
Pathergy/poor wound healing | — | 48 | 55% | |
Musculoskeletal - arthralgias | — | 71 | 81% | |
Arthritis | — | 30 | 34% | |
Vascular | — | 22 | 25% | |
Aneurysm | — | 7 | 8% | |
Thrombosis | — | 21 | 24% | |
Posterior/panuveitis | — | 39 | 44% | |
Gastrointestinal inflammation | — | 10 | 11% | |
Neurological | — | 18 | 20% | |
Median BSDAI* | — | 2 | ||
Current medications | ||||
Colchicine | — | 22 | 29% | |
Azathioprine | — | 15 | 19% | |
Mycophenolate | — | 12 | 16% | |
Anti-TNF therapy | — | 16 | 21% | |
Cyclosporine | — | 3 | 4% | |
Methotrexate | — | 9 | 12% | |
Steroids† | — | 24 (7.5 mg) | 31% | |
Warfarin | — | 12 | 14% | |
